01 Growing Shift Toward High-Throughput Spatial Transcriptomics The transcriptomics market is increasingly moving from conventional RNA sequencing toward spatial approaches that measure gene expression while retaining the location of cells within tissue. Spatial information allows researchers to understand how neighboring cell populations interact and how molecular activity changes across tumors, organs, and other complex structures. Increasing throughput is making these workflows suitable for larger tissue areas and research cohorts rather than isolated experiments. High-throughput spatial analysis is therefore becoming an important part of transcriptomics market trends. In April 2026, 10x Genomics introduced its Atera spatial platform for whole-transcriptome in situ analysis. The system is designed to process more than 100 million cells annually on a single instrument while providing single-cell gene-expression information across large tissue samples.
02 Increasing Integration of Transcriptomics With Proteomics Researchers increasingly want to measure RNA and proteins within the same biological specimen instead of analyzing individual molecular layers separately. Combining these datasets can reveal whether changes in gene expression translate into corresponding cellular functions and can provide a more complete view of disease pathways and treatment responses. Same-sample analysis also reduces variability associated with comparing separate tissue sections. RNA-protein integration is consequently expanding the transcriptomics industry toward multidimensional biological profiling. In April 2025, Bruker expanded the CosMx Spatial Molecular Imager with same-slide multiomics capabilities that combine approximately 19,000 whole-transcriptome RNA targets with up to 76 protein targets at single-cell and subcellular resolution.
01 Expansion of Single-Cell Research Increases Sequencing Requirements Bulk RNA sequencing averages molecular signals across many cells and can hide rare populations or important differences between individual cells. Researchers are therefore increasingly using single-cell transcriptomics to investigate immune responses, developmental pathways, tumor heterogeneity, and disease-associated cell states. Larger studies require technologies capable of processing substantially more cells while maintaining reliable molecular information. Expansion of single-cell research is therefore strengthening transcriptomics market demand.
01 Large RNA Datasets Create Bioinformatics Bottlenecks Modern single-cell experiments generate large expression matrices that require quality control, normalization, clustering, annotation, differential-expression analysis, and biological interpretation. Laboratories can generate sequencing information faster than they can analyze it when computational infrastructure or specialist bioinformatics expertise is limited. Storage and processing requirements also rise as studies include more cells and samples. Computational complexity can consequently restrain transcriptomics market growth despite improvements in sequencing throughput.
01 Expansion of Three-Dimensional Transcriptomic Mapping Most spatial workflows analyze thin tissue sections, providing only a two-dimensional view of biological structures that naturally exist in three dimensions. Direct 3D analysis can reveal cellular neighborhoods, tissue boundaries, tumor invasion patterns, and molecular gradients that may be missed when separate sections are reconstructed computationally. This creates new applications in neuroscience, developmental biology, and cancer research. Three-dimensional molecular mapping can therefore help technology providers increase transcriptomics market share.
01 Preserving RNA Quality During Sample Preparation RNA degrades more easily than DNA, making sample collection, storage, fixation, extraction, and processing critical to transcriptomic accuracy. Degraded molecules can reduce transcript detection and introduce biases that are particularly problematic when researchers compare clinical samples collected under different conditions. Archived tissue presents an additional difficulty because fixation can fragment or chemically modify RNA. Maintaining usable molecular information across diverse sample types therefore remains a major challenge as the transcriptomics market size expands into translational research.
June 2026 Illumina launched an expanded single-cell and spatial transcriptomics workflow, integrating next-generation sequencing with advanced bioinformatics to improve gene expression analysis for translational and clinical research.
April 2026 10x Genomics introduced the latest version of its Visium HD Spatial Gene Expression platform, providing higher-resolution transcriptomic profiling to support oncology, neuroscience, and biomarker discovery research.
January 2026 Bruker Corporation completed the acquisition of NanoString Technologies, strengthening its spatial biology and transcriptomics portfolio by combining NanoString’s molecular profiling technologies with Bruker’s life science instrumentation.
October 2025 Standard BioTools Inc. (formerly Fluidigm) launched new high-plex transcriptomics workflows integrating advanced single-cell analysis and multi-omics capabilities for life science research.